1. Introduction {#sec1-pharmacy-06-00133}
===============

Patient safety is at the core of quality of health care as echoed in the Hippocratic Oath: "I will prescribe regimes for the good of my patient according to my ability and my judgment and never do harm to anyone ... In every house whenever I come, I will enter only for the good of my patient" (Excerpt from the Hippocratic Oath c. 300--400 BCE.) The Hippocratic Oath guided most doctors to be non-maleficence and beneficence for a long time \[[@B1-pharmacy-06-00133]\]. Unfortunately, these virtues in newer times are troubled by the aged predators called Medication Errors \[[@B2-pharmacy-06-00133]\].

Despite of the growing attention to patient safety, the freedom from accidental injury due to medical care or from medical error, the realisation of this apophthegm is far from long shot \[[@B3-pharmacy-06-00133],[@B4-pharmacy-06-00133],[@B5-pharmacy-06-00133]\]. Working on Patient safety has stuck a realisation that the power and complexity of modern medicine to cure and ameliorate ailments rendered hospitals as a 'not so safe place' for healing as perceived yet, those were places fraught with risk of patient harm \[[@B6-pharmacy-06-00133]\].

Long before the words "medication error" and "patient safety" came into existence, the term Iatrogenesis had been widely known amongst the medical fraternity. This ancient word, iatrogenesis, is a combination of two Greek words, Iatros (healer) and Genesis (to bring forth). Iatrogenesis is defined as the undesirable side-effects of medical interventions \[[@B7-pharmacy-06-00133]\]. Whereas, National Coordinating Council for Medication Error-reporting Programme (NCC MERP) defines medication error as "A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing, order communication, product labelling, packaging, and nomenclature, compounding, dispensing, distribution, administration, education, monitoring, and use. While near misses are defined as an event, situation, or error that took place but was captured before reaching the patient" \[[@B8-pharmacy-06-00133],[@B9-pharmacy-06-00133]\].

Medication Errors, once known as a diseases of medical progress \[[@B10-pharmacy-06-00133]\] in the 1950s and a 'noxious episodes' \[[@B11-pharmacy-06-00133]\] in 1960s, evolved into a vast, profound, inevitable, and ineluctable reality of medication-based therapy. The cause of this evolution was the repercussions of current medicalisation of diseases and had dreadful effect on patients and medical staff alike \[[@B12-pharmacy-06-00133]\]. Although hospitals and healthcare professionals (HCPs) avow and aim for providing the safest care possible, things may go wrong leading to extensive toll of inadvertent clinical iatrogenesis.

In 1984, the Harvard Medical Practice Study (HMPS) findings sparked the need for replication of HMPS in Australia, New Zealand, Denmark, the United Kingdom, and Canada, and altogether reported higher rates of adverse events (9--13%) and, roughly 50% of the adverse events were considered preventable \[[@B13-pharmacy-06-00133],[@B14-pharmacy-06-00133],[@B15-pharmacy-06-00133],[@B16-pharmacy-06-00133],[@B17-pharmacy-06-00133]\]. The consecutive evidences of medication errors recorded in that decade transcended into the wake of sensational report by the Institute of Medicine (IOM), Building a Safer Health System, November 1999. This report has changed all the existing estimates of medication errors and claimed as many as 98,000 people die every year because of iatrogenesis in the United States of America (USA) alone. Followed by the United Kingdom (UK) Department of Health's review of patient safety in the National Health Service (NHS), 2000, 'An organisation with a memory', extrapolated iatrogenic figures from the US studies to estimate that 250,000 patients might be iatrogenic suffering as a result of NHS care costing around £400 million per year, and the additional hospital bed days cost as much as £2 billion annually \[[@B18-pharmacy-06-00133]\].

By 2013, various researchers who provided an estimate of 210,000 deaths per year were associated with preventable adverse events (PAEs) in hospitals using the Global Trigger Tool (GTT) \[[@B19-pharmacy-06-00133]\]. These estimates were the lower limits of weighted averages of the various contemporary studies. With incomplete medical records these proposed values can be projected to an estimate of 400,000 per year premature deaths associated with preventable harm. Further, serious harm seems to range 10- to 20-fold more common than lethal \[[@B20-pharmacy-06-00133]\].

On the other hand, these estimates of medication errors are inundated for not being absolute as it is pragmatically difficult to compute and arrive at prevalence rate of the errors due to the varying definitions of medication errors and classification systems. Usually, the reported rates vary depending on the denominator used (e.g., number of patients, number of prescriptions, number of doses or a specific medication etc.). The challenge of reaching a nearest possible estimate is compounded by differences in health care system organizations and the availability and use of medication error-reporting systems \[[@B21-pharmacy-06-00133]\]. Whilst in the Indian scenario, the current workload on doctors (1:1800) and nursing staff (1.7 for every 1000 patients) has left breaches in patient safety \[[@B22-pharmacy-06-00133]\]. Recently, blotched mass sterilisations and cataract surgeries in 2014 remain stark are reminders of inadequate accountability, limited infrastructure, and low-quality health services in India's health care sector \[[@B23-pharmacy-06-00133]\].

With this scenario, sustaining a well-established medication error-reporting system is an uphill battle in any developing economic state. Although there is a lack of medication error-reporting system in India, the few studies that have been conducted on medication errors and rate of errors ranged between 15.34% and 25.7%, respectively, in hospitalized patients \[[@B24-pharmacy-06-00133],[@B25-pharmacy-06-00133]\]. The confidence in these numbers suffer due to severe under reporting and lack of uniform standards in gauzing the errors \[[@B26-pharmacy-06-00133]\]. This scenario warrants that designing an indigenous error-reporting programme is essential to understand the nature and extent of medication errors to encourage patient safety.

2. Methodology {#sec2-pharmacy-06-00133}
==============

At the study site, the Dept. of Clinical Pharmacy has taken an initiative to design and implement medication error-reporting and a monitoring programme using the principles of prospective, voluntary, open, anonymous, and stand-alone surveillance in an 1800-bed tertiary care teaching hospital located in South India. Further to support the system a five-membered expert panel was created to oversee its functions. Members were drawn from various specialities within the hospital and were set to meet once every two months or, otherwise, on the basis of need to evaluate, monitor, and redress the medication errors and any other issues pertaining to the patient safety. NCC MERP's definition of medication error was adapted for this study purpose and any deviation from the standard procedure involved in the prescribing, transcribing, dispensing, administration, and monitoring were considered as medication errors. The elements of the deviation are tabulated in [Table 1](#pharmacy-06-00133-t001){ref-type="table"} of results.

For the purpose of the study, a prospective, observational study design was adapted and carried out for three years. MEs involving in-patients of either sex admitted to the wards of General Medicine, Emergency Medicine, Intensive care units, Surgery, and Obstetrics and Gynaecology were included in the study. The reporters were given the choice to remain anonymous and Institutional human ethics committee approval was obtained to carry out the study.

The functional aspects of the medication error-reporting system include:*Voluntary*: Health care professionals can report the medication errors without any compulsion.*Open*: Any health care professional of any specialisation of any status can report any medication error.*Anonymous*: Health care professionals can remain anonymous while reporting the medication error.*Stand-alone*: Thus, reported medication errors were pooled into a database and the data was secured and not shared outside the purview of the review committee.*Exploratory*: Reported medication errors were evaluated with the concept of "cause and effect"*Paper and electronic based database*: Reporter can use either of the available modes to report an error. HCPs were requested to avoid reporting the same medication error by using two different modes.

Medication Error reports were accepted from all the health care professionals of the different specialities irrespective of their status and types of services they provided. As mentioned earlier, the reporters were not obligated to disclose their identity while reporting. They were requested to report the error with a detailed description using any of the provided modes of reporting. For the study purpose, a system was created wherein a reporter can choose to report the error using paper-based system, electronic system and or telephone-based system.

2.1. Paper-Based System {#sec2dot1-pharmacy-06-00133}
-----------------------

The Voluntary Medication Error-reporting Form (vMERF) was designed by clinical pharmacists after observing the MedWatch^TM^, Institute for Safe Medication Practices (ISMP), ISMP-Canada, National Co-ordination Centre Medication Error-reporting Programme (NCC MERP), Joint Commission: Accreditation, Health Care, Certification (JCAHO) sentinel event reporting programs. Draft voluntary medication error-reporting form was circulated to all health care professionals for their feedback, and suggestions on utilisation of the vMERF were considered and incorporated as appropriate.

The final vMERF includes following elements:Medication Error's date and timePatient's age and genderDescription of the medication errorAt which stage the medication error has occurredWhether the medication error has reached the patient, and if reached, did the error warranted for any interventionPersonnel who identified and reported the medication errorPlace where the medication error has occurredNCC MERP's medication error outcome categoryContributing factorsDetails of the medication involvedOptional details of the reporter.

2.2. Electronic and Telephonic Reporting System {#sec2dot2-pharmacy-06-00133}
-----------------------------------------------

To make reporting the ME simplified, an intranet system was developed by the clinical pharmacists and incorporated into the hospital information system (HIS) portal, wherein any HCP can log into their HIS portal account and can report a ME. The electronic form contains same elements as that the of paper form to report an error. The committee members can view and respond to these errors spontaneously. For instant reporting and immediate attention, a telephonic system was created. The speed dial telephone numbers of the expert panel and the clinical pharmacists were widely publicised in the hospital. Any HCP who wishes to use this system can dial the assigned numbers throughout the day and report an error. Use of either system could compromise the reporter's anonymity and this was a limitation.

2.3. Implementation of the System {#sec2dot3-pharmacy-06-00133}
---------------------------------

To create awareness on the importance of reporting the MEs and encourage spontaneous reporting by health care professionals, "Dear Health Care Professional" letters were drafted by the clinical pharmacists under the guidance of expert panel and distributed amongst all HCPs. Patient safety classes were conducted to the HCPs by the clinical pharmacists wherein the expert committee's feedback letters were provided to the health care professionals. Further, these classes were liaised with the interdisciplinary members of the hospital and aimed at emphasising the need for reporting of medication errors without any fear.

2.4. Collection of Reports {#sec2dot4-pharmacy-06-00133}
--------------------------

Drop boxes were made available at all nursing stations for easy access to paper vMERFs along with the facility to drop the filled forms. These forms were collected every 24 h. When a medication error report was dropped in one of the drop boxes, a clinical pharmacist would personally collect the form and follow up with the concerned HCPs to collect supportive information on what factors were involved in this error, how best the error could have been avoided, and any missing information in the report. Wherever possible, appropriate data pertaining to the reported errors was collected from the various data sources such as patient's case file, interaction with other health care professionals, patients and their care providers etc. The reporters themselves were asked to mention the contributing factors involved in the error, such as work load, distractions, newer staff, ambiguous communications etc.; thus, the reported contributing factors of the respective medication errors were rather subjective but not quantified, which was another limitation.

2.5. Assessment of the Reports {#sec2dot5-pharmacy-06-00133}
------------------------------

During the analysis, a clinical pharmacists presented each of the reported error to the panel regularly twice a week to understand how an error has occurred. Their pattern, contributing factors, and root causes were closely monitored. NCC MERP's Medication Error Index, which classifies an error according to the severity of the outcome was adopted to assess the severity of the reported errors. According to the index, the outcomes were classified from Category A to Category I ([Figure 1](#pharmacy-06-00133-f001){ref-type="fig"}). Based on these findings, medication error preventive strategies were developed accordingly, e.g., high risk medication tags to caution the end user, separation of look-alike and sound-alike drugs and train pharmacists etc. Data analysis was done using descriptive statistics.

Wherever the patient identifiers were available, they were followed-up until discharge to ensure that the medication error has been addressed appropriately. Identifier details of the patient and other information related to the error were kept confidential.

3. Results {#sec3-pharmacy-06-00133}
==========

A total of 1310 errors were reported; the highest number of medication errors occurred during the medication administration stage \[501 (38.2%)\], followed by prescription errors \[243 (18.5%)\], dispensing errors \[223 (17%)\], procurement related errors \[223 (17.02%)\], and lastly, transcription errors \[120 (1.29%)\] were reported.

The majority of the medication errors were reported from the department of emergency medicine \[458 (35%)\] followed by Surgery and Obstetrics and Gynaecology specialities \[304 (23%)\]. Nonchalant operational conditions have resulted in the fewer medication errors \[256 (19%)\] in general medicine wards. During the study period, clinical pharmacists reported the highest medication errors \[674 (51%)\], followed by nursing staff and doctors \[409 (31%)\] and \[227 (17%)\] respectively.

The majority of the reported medication errors belonged to Category A \[432, (33%)\], where the circumstances were potential to cause an error, while the least belonged to the Category F \[1 (0.07%)\]. None of the reported medication errors had outcomes corresponding to the Category G and above. These results were represented in Graph 1.

**Graph 1.** NCC MERP's categorizing index of the reported medication errors.

Work shifts were classified as work shift 1 (08:00--14:00 h), 2 (14:00 to 20:00 h), and 3 (20:00 h--06:00 h), wherein, majority of medication errors were reported during third work-shift \[425 (32%)\], while the fewer were reported during first work-shift \[407 (31%)\]. Over all, the difference in medication errors reported during three work shifts was limited. Graph 2 represents the distribution of errors over different work-shifts.

**Graph 2.** Distribution of medication errors occurred over different work-shifts.

Our study reveals that the highest medication errors occurred due to distractions during work (473), while the lowest were due to calculation errors (55). Graph 3 reflects the distribution of various contribution factors causing the medication errors.

**Graph 3.** Distribution of contributing factors of medication errors.

Of the medicines implicated in the medication error reports, antipyretics/analgesics \[255 (19.46%)\] were the main ones, followed by antibiotics \[206 (15.72)\]. The detailed distribution of the medicines implicated are tabulated in [Table 2](#pharmacy-06-00133-t002){ref-type="table"}.

4. Discussion {#sec4-pharmacy-06-00133}
=============

The incidence of MEs at the study site was 6.4%. While, in India, the incidence of medication errors ranged between 3% and 33.4% \[[@B27-pharmacy-06-00133],[@B28-pharmacy-06-00133]\]. Such a broad range in the ME rates may be attributable to the disparities in the methodologies adopted in identifying and reporting the errors and its associated variables such as definition of medication error adapted, type of the medication error-reporting implemented, nature of the hospital, i.e., workforce and work load, occupancy ratio, etc., duration of the study and type of the patients followed \[[@B29-pharmacy-06-00133],[@B30-pharmacy-06-00133],[@B31-pharmacy-06-00133],[@B32-pharmacy-06-00133]\].

Enforcing a mandatory reporting system may lead to coercing the covert of reporting medication errors within the HCPs.

On the other side, voluntary reporting may not be absolute as HCP's intellectual domains on overall awareness on MEs and what, how and where to report, and the ability to handle the repercussions of reported errors without resorting to the blame culture influences the overall reporting trends. Hence, many errors remain under-reported. In Barach et al.'s study, the under-reporting of MEs is estimated to vary from 50% to 60% annually and reporting is usually done in an informal manner. Although, errors are usually discussed verbally at morbidity or mortality review meetings without formal written reports \[[@B33-pharmacy-06-00133]\]. Implementation of medication safety practices and improvement of patient safety domains remains a mirage san written reports.

Across the globe, the incidence of medication errors is almost certainly low and not often reliable due to under-reporting tendencies. Reasons for underreporting may span across apprehension of reprisal, lawsuit concerns, time constraints, the uncertainty of which errors to report, concerns of implicating other HCPs, peer pressures, and lack of feedback on reported MEs \[[@B34-pharmacy-06-00133],[@B35-pharmacy-06-00133]\]. Further, the information on incidences of medication errors that are reported in selected clinical specialisations with focus on certain medications were well documented; however, the overall data pertaining to the incidence of medication errors occurring in a complete hospital setup like ours is limited. Despite detecting and reporting the medication errors, quantifying these errors' rates is not an easy task. Anonymous reporting may encourage the reporters to report an error, but addressing patient safety under the anonymous tag may get compromised by repetitive and preventable errors \[[@B36-pharmacy-06-00133]\]. Further, enormous diversity in the taxonomy used in reporting medication errors, and expressing the error rates using various denominators such as patient days, for 100 prescription, for 100 doses, etc., is an arduous task in harmonising the overall error rate \[[@B37-pharmacy-06-00133]\].

4.1. Overall Trend in Voluntary Reporting of Medication Errors {#sec4dot1-pharmacy-06-00133}
--------------------------------------------------------------

All medication errors were reported using a paper-based system as it may relatively protect the anonymity of the reporter compared to electronic and telephonic systems. The doctors, nursing staff, and clinical pharmacists reported 227 (17.3%), 409 (31%) and 674 (51.4%) errors, respectively, in five selected different study units. Of these errors, doctors reported medication administration errors \[72 (31%)\], majorly followed by prescription errors \[49 (22%)\], and dispensing errors \[31 (14%)\] and so on. Amongst the errors reported by the nursing staff, the majority were procurement errors \[89 (22%)\] followed by transcription and administration errors \[70 (17%)\] each. Lastly, clinical pharmacists reported administration errors \[211 \[n = 674 (31%)\] followed by dispensing 138 (21%) and prescription errors \[129 (19%)\]. In our study setting, clinical pharmacists reported the majority of the medication errors compared to other health care professionals for two reasons. Firstly, the amount of time CPs spend with their patients in the wards and secondly, the reporting system is driven by CPs themselves.

Further, this reporting system is the first of its kind in our setting, and factors such as availability of the time for HCPs for reporting an error, their workload, fear of legal liability, misconceptions on job threat, adverse economic effects, concerns regarding protecting the professional status at the workplace, and other negative consequences of reporting might have played an important role on why there were fewer errors reported by the doctors and nursing staff \[[@B38-pharmacy-06-00133]\]. In order to understand and overcome these factors, one-to-one and group discussions were conducted periodically by the expert committee, reinforcing the non-punitive and anonymous principles of the reporting system.

Another reason for lower medication error-reporting rate compared to the earlier mentioned studies, which was we identified during casual discussions with health care professionals, was "preference" of doctors and nursing staff, to keep medication errors in-house. Wherein, believing loyalty to colleagues, and "whistle-blowing" were both unsupportive and unethical. Similar opinions were quoted in age old Webb et al.'s study \[[@B38-pharmacy-06-00133]\]. Another reason for lower reporting of Medication errors is that, they often instigate remorse in the implicated personnel. Adapting a mandatory reporting system will drastically affect the overall reporting trends and having a voluntary reporting system is by no means an antidote for the complacency attitude amongst HCPs. We presume, the extent of such barriers may influence the reporting rates across the developing countries.

One of the strategies to reduce the impact of such preferences on overall reporting rate is utilisation of clinical phatrmacists in medication error-reporting systems. They can support the HCPs by maintaining the confidentiality of errors, obtaining detailed medication history from the patients and their care takers and provide efficient medication reconciliation, and thus reducing the medication errors \[[@B39-pharmacy-06-00133],[@B40-pharmacy-06-00133]\]. The utilisation of the clinical pharmacists in the current study set-up has been the reason for reporting the majority of the errors and, thus, reducing associated implications.

4.2. Outcomes of the Reported Errors {#sec4dot2-pharmacy-06-00133}
------------------------------------

Most of the medication errors were reported to have the potential to cause error \[432, (32.9%)\]. Followed by errors that occurred and did not reach the patient \[413 (31.5%)\]. These errors were intercepted by the clinical pharmacist during the ward rounds and intensive follow-up of the patients and prevented them from manifesting into actual errors. Category A errors are the errors which have the potential to cause an error, and Category B errors are actual errors which were identified and prevented before reaching the patient. Distractions while filling the prescriptions and drawing the medicine into syringes, illegible hand writing in prescriptions etc., have potential to cause an error if not rectified immediately. Further, when the Category A errors are left unattended, they may evolve into Category B level errors, that are just might reach the patient if not stopped by the HCPs. From there onwards, the progress of the category of these errors depends on to what level the patient was affected. The range of such errors is confined between Category C and I, wherein category C medication errors are those that have reached the patient but did not affect safety, and category I errors might have caused patient death.

Employing double checks on medication usage at every step by those whoever are responsible in handling the drugs can reduce medication errors effectively than any sheer luck interceptions. As clinical pharmacists are bestowed with more patient bed-side time, they intercepted the potential errors and reported. Implementation of the Computerised Physician Order Entry systems (CPOE) could reduce the progression of errors from Category A to Category I. However, use of such systems is modest in the resource restricted countries. Towards inculcation of patient safety culture amongst all HCPs, we encouraged them to report voluntarily whatever they deemed an error irrespective of their severity. This has encouraged the HCPs to report Medication Errors. Giving incentives to the HCPs could improve the overall rate of ME reporting, but it may not be viable model in the developing countries.

4.3. Contributing Factors {#sec4dot3-pharmacy-06-00133}
-------------------------

Distractions were one of the major contributing factors for reported medication errors followed by increased workload and incoherent communications. Being a 1800-bed hospital with a constant 80% occupancy rate and housing hundreds of HCPs, the contributing factors such as distractions and work load are likely to be more. A total of 2560 contributing factors were associated with reported 1310 medication errors (a medication error can have multiple contributing factors).

Further, we have identified that the majority of the medication errors were reported during night shifts 425, \[(32.4%) n = 1310\] (20:00 to 08:00 h) followed by 407, \[(31.06%) n = 1310\] during the first shift (08:00 to 14:00 h). The reporting rate of medication errors during night seems to be lesser compared to other shifts. HCPs regularly sacrifice their breaks to provide patient care, therefore during the night shifts bright lights, rest breaks, power naps, and exercises, can be used to provide relief from the symptoms of fatigue. To reduce distractions and improve interpersonal communications, CPOE systems can be employed and thus improving patient safety \[[@B41-pharmacy-06-00133]\].

5. Conclusions {#sec5-pharmacy-06-00133}
==============

As a considerable number of MEs were preventable, it is important to develop and implement strategies that are unique to the work environment to try to overcome such MEs in the future. Intense monitoring of patients for potential MEs and its early detection and reporting by all HCPs may result in improved therapeutic outcomes and decreased unnecessary healthcare related mortality.

Medication errors, such as the ones reported here, not only harm the patients, but also wreck the confidence of HCPs involved. Reporting systems should be designed to encourage and instil the confidence in reporting the errors openly by HCPs. Our study laid foundations for successful establishment of medication error-reporting and monitoring programme in a tertiary care teaching hospital and is contributing significantly towards the patient safety involving all stakeholders. With greater emphasis on a non-punitive course of corrective measures and anonymity of the HCPs on handling medication errors, improves the overall reporting in terms of quality and quantity. Fault finding attitudes should be replaced with open, inclusive, and common improvement agendas involving all HCPs alike for fortifying patient safety. Clinical pharmacists, working in the close liaison with other HCPs can provide excellent support in promoting and sustaining patient safety.

This study is indeed a pilot study to understand the implications of Medication Errors at our study site. The three years have given us deeper insights into how HCPs react to the varying levels of MEs. We promptly discussed the MEs with concerned HCPs on the ethical basis to alert them regarding such happenings. HCPs intervened on time to minimise the impact of these errors. This learning experience has helped all HCPs to be cautious of such happenings in the future, and they emphasised the importance of prevention of errors to the associated team members. In this way, this study has contributed to the early steps towards patient safety. Overall, this is a first of its kind study in our region and we are trying to balance the interests of all stakeholders, most importantly, the patient's.
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pharmacy-06-00133-t001_Table 1

###### 

Detailed distribution of Medication errors across various stages.

  Sl. No.                                              Level                      Type of Error Identified         No. of Errors (%) (*n* = 1310)
  ---------------------------------------------------- -------------------------- -------------------------------- --------------------------------
  1                                                    Prescription               Date and time missing            9 (0.6)
  Patient details incomplete (name, age, and gender)   33 (2.5)                                                    
  Order is not in CAPS                                 31 (2.3)                                                    
  Unclear instructions                                 14 (1.06)                                                   
  Dose missing                                         71 (5.4)                                                    
  Quantity missing                                     09 (0.68)                                                   
  Frequency missing                                    37 (2.82)                                                   
  Signature of prescriber missing                      08 (0.61)                                                   
  Seal of the prescriber missing                       14 (1.06)                                                   
  Details of prescriber missing                        17 (1.29)                                                   
  Total                                                243 (18.5)                                                  
  2                                                    Transcriptional            Date and time missing            13 (0.99)
  Patient details incomplete                           17 (1.2)                                                    
  Order is not in CAPS                                 19 (1.4)                                                    
  Unclear instructions                                 01(0.07)                                                    
  Dose missing                                         32 (2.44)                                                   
  Quantity (details missing/incorrect)                 04(0.30)                                                    
  Frequency (details missing/incorrect)                07 (0.53)                                                   
  Frequency details missing                            07 (0.53)                                                   
  Overwriting                                          03 (0.22)                                                   
  Signature and seal of transcriber missing            17 (1.29)                                                   
  Total                                                120 (9.1)                                                   
  3                                                    Dispensing                 Wrong Drug                       58 (4.42)
  Wrong strength                                       Greater                    28 (2.13)                        
  Lesser                                               22 (1.6)                                                    
  Wrong dosage form                                    17 (1.29)                                                   
  Wrong Quantity                                       Fewer                      15 (1.14)                        
  More                                                 23 (1.75)                                                   
                                                                                  Substituted with another brand   22 (1.67)
  Delayed Dispensing                                   38 (2.9)                                                    
  Total                                                223 (17.0)                                                  
  4                                                    Administration             Wrong Drug                       22 (1.67)
  Wrong strength                                       Greater                    39 (2.97)                        
  Lesser                                               16 (1.22)                                                   
  Wrong dosage form                                    03 (0.22)                                                   
  Wrong time                                           Delayed beyond 1 h         68 (5.19)                        
  Administered before 1 h                              28 (2.13)                                                   
  Wrong administration technique                       10 (0.76)                                                   
  Wrong patient                                        03 (0.22)                                                   
                                                                                  Wrong route of administration    70 (5.34)
  Dose missed                                          94 (7.17)                                                   
  Document-ation                                       Incomplete documentation   15 (1.14)                        
  Delayed Documentation                                84 (6.41)                                                   
  Monitoring                                           34 (2.59)                                                   
  Storage                                              15 (1.14)                                                   
  Total                                                501 (38.2)                                                  
  5                                                    Procurement                Fail to bring                    96 (7.32)
  Insufficient Quantities                              53 (4.04)                                                   
  Substituted with other brands                        22 (1.67)                                                   
  Time taken to procure is beyond 12 h                 52 (3.96)                                                   
  Total                                                223 (17.02)                                                 
  Grand Total                                          1310 (100)                                                  

pharmacy-06-00133-t002_Table 2

###### 

Classification of medicines involved in reported medication errors.

  Class of the Drugs                 Drugs                       No. of Errors (%) (N = 1310)                 
  ---------------------------------- --------------------------- ------------------------------- ------------ -----------
  Analgesics/Antipyretics            Aceclofenac                 M01AB16                         23 (1.75)    
  Aspirin                            B01AC06                     56 (4.27)                                    
  Diclofenac                         M01AB05                     17 (1.29)                                    
  Gabapentin                         N03AX12                     16 (1.22)                                    
  Ibuprofen                          M01AE01                     08 (0.61)                                    
  Indomethacin                       M01AB01                     06 (0.45)                                    
  Mefenamic Acid                     M01AG01                     28 (2.13)                                    
  Naproxen                           M01AE02                     03 (0.22)                                    
                                     Paracetamol                 N02BE01                         61 (4.65)    
                                     Piroxicam                   M01AC01                         01 (0.07)    
                                     Pregabalin                  N03AX16                         21 (1.60)    
                                     Tramadol                    N02AX02                         15 (1.14)    
  Total                              255 (19.46)                                                              
  Anti-Arrhythmic drugs              Digoxin                     C01AA05                         3 (0.22)     
  Antibiotics                        Beta-Lactam                 Amoxicillin + Clavulanic Acid   J01CR02      16 (1.22)
                                     Cefixime +Clavulanic Acid   J01DD08                         01(0.07)     
                                     Cefotaxime                  J01DD01                         12 (0.91)    
                                     Ceftriaxone                 J01DD04                         07 (0.53)    
                                     Cefuroxime                  J01DC02                         03 (0.22)    
                                     Ciprofloxacin               J01MA02                         13 (0.91)    
                                                                 Crystalline Penicillin          J01C         16 (1.22)
  Quinolones                         Norfloxacin                 J01MA06                         13 (0.99)    
  Glycopeptide                       Vancomycin                  J01XA01                         11 (0.83)    
  Oxazolidinone                      Linezolid                   J01XX08                         19 (1.45)    
  Macrolides                         Azithromycin                J01FA10                         64 (4.88)    
  Aminoglycosides                    Gentamicin                  J01GB03                         12 (0.91)    
  Amikacin                           J01GB06                     11(0.83)                                     
  Nitroimidazoles                    Metronidazole               J01XD01                         03 (0.22)    
  Total                              206 (15.72)                                                              
  Antidiabetic                       Acarbose                    A10BF01                         8 (0.61)     
  Glimepiride                        A10BB12                     32 (2.44)                                    
  Glyburide                          A10BB01                     17 (1.29)                                    
  Insulin                            A10AC01                     43 (3.28)                                    
  Metformin                          A10BA02                     56 (4.37)                                    
  Voglibose                          A10BF03                     1 (0.07)                                     
  Total                              157 (11.98)                                                              
  Anti-Emetic                        Domperidone                 A03FA03                         81 (6.25)    
                                     Doxylamine Succinate        R06AA09                         02 (0.15)    
                                     Itopride                    A03FA07                         01 (0.07)    
                                     Metoclopramide              A03FA01                         13 (0.99)    
                                     Ondansetron                 A04AA01                         12 (0.91)    
                                     Promethazine                R06AD02                         01 (0.07)    
  Total                              110 (8.39)                                                               
  Anti-Epileptics                    Clobazam                    N05BA09                         1 (0.07)     
  Diazepam                           N05BA01                     1 (0.07)                                     
  Phenobarbital                      N03AA02                     1 (0.07)                                     
  Phenytoin                          N03AB02                     3 (0.22)                                     
  Total                              06 (0.45)                                                                
  Anti-Hypertensive                  Atenolol                    C07AB03                         21 (1.6)     
  Enalapril                          C09AA02                     04 (0.30)                                    
  Metoprolol                         C07AB02                     34 (2.5)                                     
  Propranolol                        C07AA05                     19 (1.45)                                    
  Total                              78 (5.95)                                                                
  Anti-Secretory                     Omeprazole                  A02BC01                         16 (1.22)    
                                     Pantoprazole                A02BC02                         122 (9.31)   
                                     Rabeprazole                 A02BC04                         21 (1.60)    
  Total                              159 (12.13)                                                              
  Anti-Tussive                       Ambroxol (Secretolytic)     R05CB06                         24 (1.83)    
  Dextromethorphan                   R05DA09                     13 (0.99)                                    
  Total                              37 (2.82)                                                                
  Antiviral                          Acyclovir                   J05AB01                         2 (0.15)     
  B~2-~ Agonist + Anti-Cholinergic   Salbutamol + Ipratropium    R03AL02                         127 (9.69)   
  Total                              127 (9.69)                                                               
  Diuretics                          Furosemide                  C03CA01                         2 (0.15)     
  Mannitol                           B05BC01                     6 (0.45)                                     
  Spironolactone                     C03DA01                     02 (0.15)                                    
  IV Fluids                          Hypertonic Solutions        B05DB                           02 (0.15)    
  Normal saline                      B05CB02                     66 (5.03)                                    
  Ringer Lactate                     B05BB01                     15 (1.14)                                    
  Total                              83 (6.33)                                                                
  Minerals /Vitamins                 Calcium                     A12A                            16 (1.22)    
  Multi-Vitamins                     A11                         06 (0.45)                                    
  Thiamine                           A11DA01                     5 (0.38)                                     
  Vitamin K                          B02BA                       01 (0.07)                                    
  Total                              28 (2.13)                                                                
  Steroids                           Dexamethasone               H02AB02                         21 (1.60)    
  Hydrocortisone                     H02AB09                     16 (1.22)                                    
  Prednisolone                       H02AB06                     11 (0.83)                                    
  Progesterone                       G03DA03                     03 (0.22)                                    
  Total                              51 (3.89)                                                                
